Association of bile acid composition with synthetic pathways and efficacy of bezafibrate in cholestatic liver disease
These findings indicate that while BZF effectively suppresses the classic pathway, alternative pathway activity may compromise its therapeutic efficacy in treatment-resistant cases, highlighting the need for novel therapies inhibiting the alternative pathway in patients with inadequate response to BZF.
Authors
- Atsushi Tanaka (ORCID: https://orcid.org/0000-0003-3352-7661)
- Naoshi Horiba (ORCID: https://orcid.org/0000-0003-0853-5635)
- Yoshinari Asaoka (ORCID: https://orcid.org/0000-0002-2805-8226)
- Atsuko Higashida
- Shuichi Ohtomo
- Akihito Takeuchi (ORCID: https://orcid.org/0000-0003-4332-4075)
- Akira Honda (ORCID: https://orcid.org/0000-0003-0902-8272)
- Manami Iida
- Ryo Miura
Institutions
- Chugai Pharma (United States) (US)
- Tokyo Medical University Ibaraki Medical Center (JP)
- Teikyo University (JP)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2025-09-02
- DOI
- https://doi.org/10.3350/cmh.2025.0575
- Citations
- 1
- Primary Topic
- Drug Transport and Resistance Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 1.05